AirSculpt Technologies, Inc. (AIRS) 株式分析

企業概要

AirSculpt Technologies, Inc. operates primarily as a holding company for EBS Intermediate Parent LLC, which specializes in providing body contouring procedure services across the United States and Canada. The firm functions within the healthcare sector, specifically classified under the medical care facilities industry, indicating its focus on specialized clinical environments and procedural services rather than broad pharmaceutical or device manufacturing. The company's market capitalization stands at $191.18M, while its trailing twelve-month revenue totals $151.82M, supported by a workforce of 330 employees. These financial metrics suggest the organization occupies a mid-cap position within the aesthetic medicine niche, where revenue generation is significant relative to its valuation but operates with specific regional constraints. The disparity between its substantial annual revenue and modest market cap highlights a valuation structure that may reflect investor sentiment regarding its profitability trajectory or the capital-intensive nature of its service delivery model in a competitive specialty market.

財務健全性

AirSculpt Technologies reported trailing twelve-month revenue of $151.82M, yet recorded a net income of -$11,667,000, revealing a significant gap between top-line performance and bottom-line profitability that points to high operating leverage or substantial expense burdens. Despite the net loss, the company generated an EBITDA of $7.95M, suggesting that operational cash earnings remain positive even before interest, taxes, depreciation, and amortization costs are deducted. The company produced free cash flow of $5.17M, which indicates a degree of financial flexibility to fund operations or invest in facilities despite the reported accounting losses. Profitability analysis shows a gross margin of 66.0%, reflecting the high-margin nature of service-based medical procedures, while the operating margin of -4.6% and profit margin of -7.7% demonstrate that general and administrative expenses are eroding those gross profits. Liquidity and leverage metrics show a cash position of $8.45M against total debt of $83.57M, resulting in a debt-to-equity ratio of 95.28, which characterizes the balance sheet as highly leveraged rather than conservative. The current ratio stands at 0.55, indicating that current liabilities exceed current assets and signaling potential short-term liquidity challenges in meeting obligations as they fall due. Furthermore, the return on equity is -14.1% and the return on assets is -1.5%, metrics that reveal that management has not yet achieved positive capital efficiency and that the company is currently destroying value relative to its shareholders' equity and asset base.

バリュエーション評価

Valuation multiples for AirSculpt Technologies include a trailing P/E ratio of N/A due to negative earnings, and a forward P/E of -90.33, implying that the market is pricing in future earnings recovery rather than current performance. The price-to-book ratio is 1.99, suggesting that the market values the company at nearly double its net asset book value, which may reflect intangible assets, brand equity, or optimistic growth expectations in the body contouring sector. Alternative valuation metrics such as the price-to-sales ratio of 1.26 and an EV/EBITDA of 33.51 provide context for the company's valuation relative to its revenue generation and enterprise cash flows, respectively. Historical price data shows a 52-week high of $12.00 and a 52-week low of $1.51, and given the recent market context, the current trading price sits significantly below the 52-week high, reflecting the volatility and recent performance trends of the stock. The beta value is 2.27, indicating that the stock price exhibits high volatility and is expected to move with more than twice the magnitude of the broader market index during periods of market fluctuation.

Growth & Income

The company experienced a revenue growth rate of -14.6% year-over-year, while earnings growth is listed as N/A due to the negative net income, indicating a contraction in top-line business rather than an acceleration in profitability. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute cash to shareholders but instead retains earnings, although the current negative earnings make traditional reinvestment for growth difficult under standard models. The absence of a dividend yield confirms that the firm is not a yield-generating asset, aligning with its status as a growth-oriented or turnaround candidate where capital is theoretically needed for expansion, though the negative revenue growth complicates this narrative. Overall, the growth and income profile is characterized by declining revenue, negative returns on capital, and a lack of dividend distribution, presenting a distinct risk-reward dynamic for investors monitoring the medical care facilities sector.